RespireRx Pharmaceuticals Inc (RSPI)

[apu_85]

GFP, I am long RSPI and the dilution is concerning although a necessary evil. I'm cautiously optimistic that there is enough potential in the respiratory markets, along with "multiple shots on goal", that it can work. I'm more interested in the Ampakines than Dronabinol. I am no clinician but given the stigma around cannibinoids, I think this is going to be a tough hill climb to get it mainstream. Also, synthetic marijuana is becoming more of an issue on the street which doesn't help. Hopefully this trial proves solid efficacy and the question only becomes adoption.

On the flip side, I see huge opportunity for the Respiratory Depression market. I am holding my breath (no pun intended) and my positions until the Ampakines play out. Huge market, huge partnership opportunity. Could go right in a few areas there.

I've been impressed with the leadership since Lippa took over. Time and again, they have told us what they want to do, and they have done it. They've checked a lot of things off the list, and with Manuso, I think they are have someone who can max out the value/potential.

I'm optimistic for a good 2016 for RSPI.